Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study.

"Disclosure KD, SL, AT, and AN are employees of Carelon Research, Inc., which received funding for the conduct of this study from AstraZeneca. KD and SL are stockholders of Elevance Health. MP, KR CN, and NF are employees and stockholders of AstraZeneca. DM has received payment for consultant services from AstraZeneca and GSK; personal fees from Up to Date, personal fees from Genentech; and has been an expert witness for the Schlesinger Law Firm. GC has received research grant funding and payment for consultant services from AstraZeneca, GSK, and Chiesi Farmaceutici, and received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pulmonx. The authors report no other conflicts on interest in this work."

"This study was funded by AstraZeneca."